190 related articles for article (PubMed ID: 20637495)
1. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
Tehrani S; Mobarrez F; Antovic A; Santesson P; Lins PE; Adamson U; Henriksson P; Wallén NH; Jörneskog G
Thromb Res; 2010 Sep; 126(3):e225-31. PubMed ID: 20637495
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.
Mobarrez F; He S; Bröijersen A; Wiklund B; Antovic A; Antovic J; Egberg N; Jörneskog G; Wallén H
Thromb Haemost; 2011 Aug; 106(2):344-52. PubMed ID: 21614411
[TBL] [Abstract][Full Text] [Related]
3. Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes.
Tehrani S; Mobarrez F; Lins PE; Adamson U; Wallén HN; Jörneskog G
Diab Vasc Dis Res; 2013 Nov; 10(6):483-8. PubMed ID: 23823849
[TBL] [Abstract][Full Text] [Related]
4. Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism.
Zolcinski M; Ciesla-Dul M; Undas A
Thromb Haemost; 2012 Jun; 107(6):1180-2. PubMed ID: 22371154
[No Abstract] [Full Text] [Related]
5. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
[TBL] [Abstract][Full Text] [Related]
6. Altered plasma fibrin clot properties in essential thrombocythemia.
Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions.
Hamada M; Sugimoto M; Matsui H; Mizuno T; Shida Y; Doi M; Fukushima H; Nishio K; Yoshioka A; Shima M
Thromb Haemost; 2011 Feb; 105(2):313-20. PubMed ID: 21136018
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
9. Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study.
Mobarrez F; Egberg N; Antovic J; Bröijersen A; Jörneskog G; Wallén H
Thromb Res; 2012 Jan; 129(1):95-7. PubMed ID: 22035651
[No Abstract] [Full Text] [Related]
10. Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry.
Labiós M; Martínez M; Gabriel F; Guiral V; Martínez E; Aznar J
Thromb Res; 2005; 115(4):263-70. PubMed ID: 15668185
[TBL] [Abstract][Full Text] [Related]
11. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
Sanguigni V; Pignatelli P; Lenti L; Ferro D; Bellia A; Carnevale R; Tesauro M; Sorge R; Lauro R; Violi F
Circulation; 2005 Feb; 111(4):412-9. PubMed ID: 15687128
[TBL] [Abstract][Full Text] [Related]
12. Effect of rosuvastatin on risk markers for venous thromboembolism in cancer.
Ades S; Douce D; Holmes CE; Cory S; Prior S; Butenas S; Callas P; Cushman M
J Thromb Haemost; 2018 Jun; 16(6):1099-1106. PubMed ID: 29575637
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.
Oka H; Ikeda S; Koga S; Miyahara Y; Kohno S
Heart Vessels; 2008 Jul; 23(4):249-56. PubMed ID: 18649055
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia.
Takemoto M; Ishikawa T; Onishi S; Okabe E; Ishibashi R; He P; Kobayashi K; Fujimoto M; Kawamura H; Yokote K
Diabetes Res Clin Pract; 2013 Apr; 100(1):e26-9. PubMed ID: 23312613
[TBL] [Abstract][Full Text] [Related]
15. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
Orem C; Uydu HA; Yilmaz R; Gökçe M; Baykan M; Eminagaoglu S; Orem A
Jpn Heart J; 2004 Nov; 45(6):977-87. PubMed ID: 15655273
[TBL] [Abstract][Full Text] [Related]
16. Platelet-derived microparticles during and after acute coronary syndrome.
Skeppholm M; Mobarrez F; Malmqvist K; Wallén H
Thromb Haemost; 2012 Jun; 107(6):1122-9. PubMed ID: 22371053
[TBL] [Abstract][Full Text] [Related]
17. Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study.
Walter T; Szabo S; Suselbeck T; Borggrefe M; Lang S; Swoboda S; Hoffmeister HM; Dempfle CE
Clin Drug Investig; 2010; 30(7):453-60. PubMed ID: 20441243
[TBL] [Abstract][Full Text] [Related]
18. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
Bays HE; Schwartz S; Littlejohn T; Kerzner B; Krauss RM; Karpf DB; Choi YJ; Wang X; Naim S; Roberts BK
J Clin Endocrinol Metab; 2011 Sep; 96(9):2889-97. PubMed ID: 21752880
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin.
Pignatelli P; Sanguigni V; Lenti L; Loffredo L; Carnevale R; Sorge R; Violi F
J Thromb Haemost; 2007 Jun; 5(6):1170-8. PubMed ID: 17388962
[TBL] [Abstract][Full Text] [Related]
20. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
